Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Ulcerative colitis impairs the acylethanolamide-based anti-inflammatory system reversal by 5-aminosalicylic acid and glucocorticoids.

Suárez J, Romero-Zerbo Y, Márquez L, Rivera P, Iglesias M, Bermúdez-Silva FJ, Andreu M, Rodríguez de Fonseca F.

PLoS One. 2012;7(5):e37729. doi: 10.1371/journal.pone.0037729. Epub 2012 May 25.

2.

Peroxisome proliferator-activated receptors family is involved in the response to treatment and mild clinical course in patients with ulcerative colitis.

Yamamoto-Furusho JK, Jacintez-Cazares M, Furuzawa-Carballeda J, Fonseca-Camarillo G.

Dis Markers. 2014;2014:932530. doi: 10.1155/2014/932530. Epub 2014 Dec 8.

3.

Quantitive cytokine mRNA expression profiles in the colonic mucosa of patients with steroid naïve ulcerative colitis during active and quiescent disease.

Matsuda R, Koide T, Tokoro C, Yamamoto T, Godai T, Morohashi T, Fujita Y, Takahashi D, Kawana I, Suzuki S, Umemura S.

Inflamm Bowel Dis. 2009 Mar;15(3):328-34. doi: 10.1002/ibd.20759.

PMID:
18942752
4.

Palmitoylethanolamide improves colon inflammation through an enteric glia/toll like receptor 4-dependent PPAR-α activation.

Esposito G, Capoccia E, Turco F, Palumbo I, Lu J, Steardo A, Cuomo R, Sarnelli G, Steardo L.

Gut. 2014 Aug;63(8):1300-12. doi: 10.1136/gutjnl-2013-305005. Epub 2013 Sep 30.

PMID:
24082036
5.

Ulcerative colitis induces changes on the expression of the endocannabinoid system in the human colonic tissue.

Marquéz L, Suárez J, Iglesias M, Bermudez-Silva FJ, Rodríguez de Fonseca F, Andreu M.

PLoS One. 2009 Sep 4;4(9):e6893. doi: 10.1371/journal.pone.0006893.

6.

Antioxidant properties of mesalamine in colitis inhibit phosphoinositide 3-kinase signaling in progenitor cells.

Managlia E, Katzman RB, Brown JB, Barrett TA.

Inflamm Bowel Dis. 2013 Sep;19(10):2051-60. doi: 10.1097/MIB.0b013e318297d741.

PMID:
23867870
7.

Ghrelin ameliorates colonic inflammation. Role of nitric oxide and sensory nerves.

Konturek PC, Brzozowski T, Engel M, Burnat G, Gaca P, Kwiecien S, Pajdo R, Konturek SJ.

J Physiol Pharmacol. 2009 Jun;60(2):41-7.

8.

[A clinical trial of rosiglitazone and 5-aminosalicylate combination for ulcerative colitis].

Liang HL, Ouyang Q.

Zhonghua Nei Ke Za Zhi. 2006 Jul;45(7):548-51. Chinese.

PMID:
17074107
9.

Intestinal steroidogenesis controls PPARγ expression in the colon and is impaired during ulcerative colitis.

Bouguen G, Langlois A, Djouina M, Branche J, Koriche D, Dewaeles E, Mongy A, Auwerx J, Colombel JF, Desreumaux P, Dubuquoy L, Bertin B.

Gut. 2015 Jun;64(6):901-10. doi: 10.1136/gutjnl-2014-307618. Epub 2014 Jul 22.

11.

Topical rosiglitazone treatment improves ulcerative colitis by restoring peroxisome proliferator-activated receptor-gamma activity.

Pedersen G, Brynskov J.

Am J Gastroenterol. 2010 Jul;105(7):1595-603. doi: 10.1038/ajg.2009.749. Epub 2010 Jan 19.

PMID:
20087330
13.

Suppression of pro-inflammatory cytokine release by selective inhibition of inducible nitric oxide synthase in mucosal explants from patients with ulcerative colitis.

Kankuri E, Hämäläinen M, Hukkanen M, Salmenperä P, Kivilaakso E, Vapaatalo H, Moilanen E.

Scand J Gastroenterol. 2003 Feb;38(2):186-92.

PMID:
12678336
14.

PPAR-gamma in ulcerative colitis: a novel target for intervention.

Bertin B, Dubuquoy L, Colombel JF, Desreumaux P.

Curr Drug Targets. 2013 Nov;14(12):1501-7. Review.

PMID:
23651165
15.

N-Acylethanolamine-hydrolyzing acid amidase inhibition increases colon N-palmitoylethanolamine levels and counteracts murine colitis.

Alhouayek M, Bottemanne P, Subramanian KV, Lambert DM, Makriyannis A, Cani PD, Muccioli GG.

FASEB J. 2015 Feb;29(2):650-61. doi: 10.1096/fj.14-255208. Epub 2014 Nov 10.

16.

Mitochondrial electron transport chain complex dysfunction in the colonic mucosa in ulcerative colitis.

Santhanam S, Rajamanickam S, Motamarry A, Ramakrishna BS, Amirtharaj JG, Ramachandran A, Pulimood A, Venkatraman A.

Inflamm Bowel Dis. 2012 Nov;18(11):2158-68. doi: 10.1002/ibd.22926. Epub 2012 Feb 28.

PMID:
22374887
17.
18.

[Localization of salazopyrin in colonic mucosa patients with ulcerative colitis].

Kitano A, Tabata A, Obayashi M, Nakagawa M, Yasuda K, Fukushima R, Okabe H, Tomobuchi M, Nakamura S, Kashima K, et al.

Nihon Shokakibyo Gakkai Zasshi. 1993 Feb;90(2):124-33. Japanese.

PMID:
8096555
19.

Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma.

Rousseaux C, Lefebvre B, Dubuquoy L, Lefebvre P, Romano O, Auwerx J, Metzger D, Wahli W, Desvergne B, Naccari GC, Chavatte P, Farce A, Bulois P, Cortot A, Colombel JF, Desreumaux P.

J Exp Med. 2005 Apr 18;201(8):1205-15. Epub 2005 Apr 11.

20.

Corticotropin-releasing factor receptor subtype 2 in human colonic mucosa: down-regulation in ulcerative colitis.

Chatzaki E, Anton PA, Million M, Lambropoulou M, Constantinidis T, Kolios G, Taché Y, Grigoriadis DE.

World J Gastroenterol. 2013 Mar 7;19(9):1416-23. doi: 10.3748/wjg.v19.i9.1416.

Supplemental Content

Support Center